Sorafenib plus valproic acid for infant spinal glioblastoma

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 6, 2010, Pages 511-514

  Rokes, Christopher Alan ^a   Remke, Mark ^c   Guha Thakurta, Nandita ^b   Witt, Olaf ^d   Korshunov, Andrey ^e   Pfister, Stephan ^d   Wolff, Johannes E ^a,b  

^a Children's Cancer Hospital   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Glioblastoma; Sorafenib; Spinal tumor; Targeted therapy; Valproic acid

Indexed keywords

CISPLATIN; DEXAMETHASONE; ETOPOSIDE; HISTONE DEACETYLASE; IFOSFAMIDE; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAF PROTEIN; SORAFENIB; TEMOZOLOMIDE; VALPROIC ACID; VINCRISTINE; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PYRIDINE DERIVATIVE;

ANISOCORIA; ARTICLE; BRAIN STEM; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CASE REPORT; CERVICAL SPINE; ELECTRON THERAPY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FACIAL NERVE PARALYSIS; FEMALE; GLIOBLASTOMA; HUMAN; HYPERBARIC OXYGEN; HYPERHIDROSIS; IMMUNOHISTOCHEMISTRY; INFANT; MUSCLE HYPOTONIA; NASOGASTRIC TUBE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPINAL CORD TUMOR; SPINAL GLIOBLASTOMA; THORACIC SPINE; TORTICOLLIS; TUMOR BIOPSY; TUMOR VOLUME; METABOLISM; MULTIMODALITY CANCER THERAPY; RADIOTHERAPY; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; COMBINED MODALITY THERAPY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MAP KINASE KINASE KINASES; NEOPLASM RECURRENCE, LOCAL; PYRIDINES; RADIOTHERAPY; RAF KINASES; SPINAL CORD NEOPLASMS; VALPROIC ACID;

EID: 77955907517     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181d74702     Document Type: Article

References (25)

1. Schellinger KA, Propp JM, Villano JL, et al. Descriptive epidemiology of primary spinal cord tumors. J Neuro-Oncol. 2008;87:173-179.
2. Cohen AR, Wisoff JH, Allen JC, et al. Malignant astrocytomas of the spinal cord. J Neurosurg. 1989;70:50-54.
3. Merchant TE, Nguyen D, Thompson SJ, et al. High-grade pediatric spinal cord tumors. Pediatr Neurosurg. 1999;30:1-5.
4. Lunardi P, Licastro G, Missori P, et al. Management of intra-medullary tumours in children. Acta Neurochir (Wien). 1993; 120:59-65.
5. Constantini S, Houten J, Miller DC, et al. Intramedullary spinal cord tumors in children under the age of 3 years. J Neurosurg. 1996;85:1036-1043.
6. Allen JC, Aviner S, Yates AJ, et al. Treatment of high-grade spinal cord astrocytoma of childhood with "8-in-1" chemotherapy and radiotherapy: a pilot study of CCG-9 Children's Cancer Group. J Neurosurg. 1998;88:215-220.
7. Wolff JE, Classen CF, Wagner S, et al. Subpopulations of malignant gliomas in pediatric patients: analysis of the HIT-GBM database. J Neuro-Oncol. 2008;87:155-164.
8. Witt O, Schweigerer L, Driever PH, et al. Valproic acid treatment of glioblastoma multiforme in a child. Pediatric Blood Cancer. 2004;43:181.
9. Wolff JE, Kramm C, Kortmann RD, et al. Valproic acid was well tolerated in heavily pretreated pediatric patients with highgrade glioma. J Neuro-Oncol. 2008;90:309-314.
10. Masoudi A, Elopre M, Amini E, et al. Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res. 2008;28:2437-2442.
11. Nakamura M, Shimada K, Ishida E, et al. Molecular patho-genesis of pediatric astrocytic tumors. Neuro-Oncology. 2007; 9:113-123.
12. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291-3310.
13. de Groot JF, Gilbert MR. New molecular targets in malignant gliomas. Current Opinion Neurol. 2007;20:712-718.
14. Faury D, Nantel A, Dunn SE, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol. 2007;25: 1196-1208.
15. Pfister S, Janzarik WG, Remke M, et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest. 2008;118:1739-1749.
16. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5:835-844.
17. Jane EP, Premkumar DR, Pollack IF. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther. 2006;319:1070-1080.
18. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5: 769-784.
19. Knupfer MM, Hernaiz-Driever P, Poppenborg H, et al. Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro. Anticancer Res. 1998;18:3585-3589.
20. Das CM, Aguilera D, Vasquez H, et al. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and syner-gistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neuro-Oncol. 2007;85:159-170.
21. Zhang G, Park MA, Mitchell C, et al. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res. 2008;14:5385-5399.
22. Baradari V, Hopfner M, Huether A, et al. Histone deacety-lase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J Gastroenterol. 2007;13: 4458-1466.
23. Martin AP, Park MA, Mitchell C, et al. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol Pharmacol. 2009;76: 327-341.
24. Wong ET, Brem S. Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. J Natl Compr Canc Netw. 2008;6:515-522.
25. Hill KL Jr, Lipson AC, Sheehan JM. Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma. J Neurosurg. 2009;111:497-503.